Clinical pharmacokinetic and pharmacodynamic monitoring for mycophenolate mofetil

Yi Min Ku, Megan McCartan, Dean S Collier

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The use of mycophenolate mofetil (MMF), in combination with cyclosporine (CsA) or tacrolimus (FK) and corticosteroids, has been shown to improve clinical outcomes through significant reduction in the incidence of acute rejection in solid organ transplant patients. A fixed oral dosing regimen of 1 or 1.5 g MMF twice daily received Food and Drug Administration approval in 1995 with no recommendations for concentration monitoring at that time. Subsequent evidence has generated substantial debate on the need of clinical monitoring for MMF. This article summarizes the rationale, evidence, and approaches of clinical monitoring, for MMF. Mycophenolic acid (MPA), the active moiety of MMF, noncompetitively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is the target enzyme for MPA. Pharmacokinetic monitoring, by use of MPA predose or MPA area under the concentration-time curve (AUC) values, and pharmacodynamic monitoring by analysis of inhibition of IMPDH have been evaluated in organ transplant patients. The possibility of drug interactions between other immunosuppressive agents has also received attention recently. The clinical implications of drug interactions are discussed in this article.

Original languageEnglish (US)
Pages (from-to)422-431
Number of pages10
JournalJournal of Pharmacy Practice
Volume18
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Mycophenolic Acid
Pharmacokinetics
Inosine Monophosphate
Drug Interactions
Oxidoreductases
Transplants
Drug Approval
Tacrolimus
Enzymes
United States Food and Drug Administration
Immunosuppressive Agents
Cyclosporine
Adrenal Cortex Hormones

Keywords

  • Mycophenolate mofetil
  • Mycophenolic acid
  • Pharmacodynamic monitoring
  • Pharmacokinetic monitoring
  • Therapeutic drug monitoring

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Clinical pharmacokinetic and pharmacodynamic monitoring for mycophenolate mofetil. / Ku, Yi Min; McCartan, Megan; Collier, Dean S.

In: Journal of Pharmacy Practice, Vol. 18, No. 6, 01.12.2005, p. 422-431.

Research output: Contribution to journalReview article

@article{a15b9837d6ca4af4b9c4619023e23420,
title = "Clinical pharmacokinetic and pharmacodynamic monitoring for mycophenolate mofetil",
abstract = "The use of mycophenolate mofetil (MMF), in combination with cyclosporine (CsA) or tacrolimus (FK) and corticosteroids, has been shown to improve clinical outcomes through significant reduction in the incidence of acute rejection in solid organ transplant patients. A fixed oral dosing regimen of 1 or 1.5 g MMF twice daily received Food and Drug Administration approval in 1995 with no recommendations for concentration monitoring at that time. Subsequent evidence has generated substantial debate on the need of clinical monitoring for MMF. This article summarizes the rationale, evidence, and approaches of clinical monitoring, for MMF. Mycophenolic acid (MPA), the active moiety of MMF, noncompetitively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is the target enzyme for MPA. Pharmacokinetic monitoring, by use of MPA predose or MPA area under the concentration-time curve (AUC) values, and pharmacodynamic monitoring by analysis of inhibition of IMPDH have been evaluated in organ transplant patients. The possibility of drug interactions between other immunosuppressive agents has also received attention recently. The clinical implications of drug interactions are discussed in this article.",
keywords = "Mycophenolate mofetil, Mycophenolic acid, Pharmacodynamic monitoring, Pharmacokinetic monitoring, Therapeutic drug monitoring",
author = "Ku, {Yi Min} and Megan McCartan and Collier, {Dean S}",
year = "2005",
month = "12",
day = "1",
doi = "10.1177/0897190005282360",
language = "English (US)",
volume = "18",
pages = "422--431",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical pharmacokinetic and pharmacodynamic monitoring for mycophenolate mofetil

AU - Ku, Yi Min

AU - McCartan, Megan

AU - Collier, Dean S

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The use of mycophenolate mofetil (MMF), in combination with cyclosporine (CsA) or tacrolimus (FK) and corticosteroids, has been shown to improve clinical outcomes through significant reduction in the incidence of acute rejection in solid organ transplant patients. A fixed oral dosing regimen of 1 or 1.5 g MMF twice daily received Food and Drug Administration approval in 1995 with no recommendations for concentration monitoring at that time. Subsequent evidence has generated substantial debate on the need of clinical monitoring for MMF. This article summarizes the rationale, evidence, and approaches of clinical monitoring, for MMF. Mycophenolic acid (MPA), the active moiety of MMF, noncompetitively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is the target enzyme for MPA. Pharmacokinetic monitoring, by use of MPA predose or MPA area under the concentration-time curve (AUC) values, and pharmacodynamic monitoring by analysis of inhibition of IMPDH have been evaluated in organ transplant patients. The possibility of drug interactions between other immunosuppressive agents has also received attention recently. The clinical implications of drug interactions are discussed in this article.

AB - The use of mycophenolate mofetil (MMF), in combination with cyclosporine (CsA) or tacrolimus (FK) and corticosteroids, has been shown to improve clinical outcomes through significant reduction in the incidence of acute rejection in solid organ transplant patients. A fixed oral dosing regimen of 1 or 1.5 g MMF twice daily received Food and Drug Administration approval in 1995 with no recommendations for concentration monitoring at that time. Subsequent evidence has generated substantial debate on the need of clinical monitoring for MMF. This article summarizes the rationale, evidence, and approaches of clinical monitoring, for MMF. Mycophenolic acid (MPA), the active moiety of MMF, noncompetitively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is the target enzyme for MPA. Pharmacokinetic monitoring, by use of MPA predose or MPA area under the concentration-time curve (AUC) values, and pharmacodynamic monitoring by analysis of inhibition of IMPDH have been evaluated in organ transplant patients. The possibility of drug interactions between other immunosuppressive agents has also received attention recently. The clinical implications of drug interactions are discussed in this article.

KW - Mycophenolate mofetil

KW - Mycophenolic acid

KW - Pharmacodynamic monitoring

KW - Pharmacokinetic monitoring

KW - Therapeutic drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=28244431736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244431736&partnerID=8YFLogxK

U2 - 10.1177/0897190005282360

DO - 10.1177/0897190005282360

M3 - Review article

VL - 18

SP - 422

EP - 431

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 6

ER -